Medical Condition News

RSS

ALR announces medical research grant awards to cure lupus

The Alliance for Lupus Research – the world's largest private funder of lupus research – today announced its most recent medical research grant awards, totaling $3.6 million, which support the ALR mission of finding better treatments and ultimately preventing and curing systemic lupus erythematosus, a debilitating autoimmune disease.

7 Apr 2011

USPTO issues notice of allowance to Mirna's mir34a patent application

Mirna Therapeutics, Inc. announced today that the United States Patent and Trademark Office has allowed patent claims related to the therapeutic application of the potent tumor suppressor microRNA, mir34a.

7 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

Scientists want to protect the optic nerve when the eye takes a blow on the battlefield or in a car wreck.

7 Apr 2011

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

GlaxoSmithKline and XenoPort, Inc. announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Horizant™ (gabapentin enacarbil) Extended-Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults. Horizant is not recommended for patients who are required to sleep during the daytime and remain awake at night.

7 Apr 2011

Workers exposed to welding fumes may face risk of developing brain damage

New research suggests that workers exposed to welding fumes may be at risk for developing brain damage in an area of the brain also affected in Parkinson's disease. The study is published in the April 6, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

Brazil's Ministry of Health, PharmaPraxis sign deal to manufacture biologic drugs

PharmaPraxis, from Axis Biotec, Cryopraxis, Silvestre Labs and CellPraxis Group, announces the formalization of an agreement with Brazil's Ministry of Health to manufacture biologic drugs.

7 Apr 2011

FDA approves Covidien's PMA application for Pipeline Embolization Device

Covidien, a leading global provider of healthcare products, today announced that it received Premarket Approval from the U.S. Food and Drug Administration for the Pipeline Embolization Device, indicated for the endovascular treatment of adults with large or giant wide-necked intracranial aneurysms in the internal carotid artery from the petrous to the superior hypophyseal segments.

7 Apr 2011

Parkinson's disease linked to increased risk of prostate cancer

University of Utah School of Medicine researchers have found compelling evidence that Parkinson's disease is associated with an increased risk of prostate cancer and melanoma, and that this increased cancer risk also extends to close and distant relatives of individuals with Parkinson's disease.

7 Apr 2011

New PSA test identifies men with prostate cancer more accurately

In a large multi-center clinical trial, a new PSA test to screen for prostate cancer more accurately identified men with prostate cancer -- particularly the aggressive form of the disease -- and substantially reduced false positives compared to the two currently available commercial PSA tests, according to newly published research from Northwestern Medicine.

7 Apr 2011

Study: New cancer drug shrinks tumors in mouse model with few side effects

A study led by researchers at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.

7 Apr 2011

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.

7 Apr 2011

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced that it has successfully completed two Phase 1a clinical studies for AVL-292, its orally-available, selective inhibitor of Bruton's tyrosine kinase (Btk).

6 Apr 2011

Strawberries may slow progression of precancerous lesions in the esophagus

Freeze-dried strawberries may be an alternative to drugs for the prevention of esophageal cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

6 Apr 2011

Asuragen launches InformThyroid, a panel of molecular markers

Asuragen, Inc. announced today the launch of Inform™Thyroid, a panel of molecular markers used on Fine Needle Aspirates (FNA) of thyroid nodules to aid physicians in the management of thyroid cancer.

6 Apr 2011

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.

6 Apr 2011

Americans concerned about thyroid cancer development from mammography

Some Americans have expressed concern, due to an erroneous media report, that the small amount of radiation a patient receives from a mammogram may significantly increase the likelihood of developing thyroid cancer. This concern simply is not supported in scientific literature.

6 Apr 2011

BioWa, OBT enter license agreement to advance ADCC programs

BioWa, Inc. and Oxford BioTherapeutics Ltd today announced that they have entered into a license agreement to provide OBT with access to BioWa's patented POTELLIGENT Technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.

6 Apr 2011

Only half of post-combat military service members having mental health issues seek treatment

Approximately 50 percent of military servicemembers returning from combat duty report experiencing a mental health issue, but only half of them have sought treatment. That is according to a recently released study titled Joining Forces America, a comprehensive survey of more than 1,000 military servicemembers, family members of servicemembers, and mental health professionals.

6 Apr 2011

Medical Condition News

ALR announces medical research grant awards to cure lupus

USPTO issues notice of allowance to Mirna's mir34a patent application

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

A2AAR-selective agonists may prevent permanent vision damage from traumatic optic nerve injury

FDA approves Horizant Extended-Release Tablets for Restless Legs Syndrome

Workers exposed to welding fumes may face risk of developing brain damage

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

Brazil's Ministry of Health, PharmaPraxis sign deal to manufacture biologic drugs

FDA approves Covidien's PMA application for Pipeline Embolization Device

Parkinson's disease linked to increased risk of prostate cancer

New PSA test identifies men with prostate cancer more accurately

Study: New cancer drug shrinks tumors in mouse model with few side effects

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Strawberries may slow progression of precancerous lesions in the esophagus

Asuragen launches InformThyroid, a panel of molecular markers

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Americans concerned about thyroid cancer development from mammography

BioWa, OBT enter license agreement to advance ADCC programs

Only half of post-combat military service members having mental health issues seek treatment

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Latest News